metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mEC - (neo)adjuvant (NA) metastatic/advanced - esophageal cancer (mEC) mEC - (neo)adjuvant (NA)
versus placebo
	nivolumab alone vs. placebo	1	-	-	-
mEC - 1st line (L1) metastatic/advanced - esophageal cancer (mEC) mEC - 1st line (L1)
versus placebo plus SoC
	pembrolizumab plus SoC vs. placebo plus SoC	1	0.73 [0.62; 0.86], 1 RCT, I2=0% conclusive unassessable degree of certainty	0.65 [0.55; 0.76], 1 RCT, I2=0% conclusive unassessable degree of certainty	-
mEC - 2nd line (L2) metastatic/advanced - esophageal cancer (mEC) mEC - 2nd line (L2)
versus Standard of Care (SoC)
	camrelizumab alone vs. Standard of Care (SoC)	1	0.71 [0.57; 0.88], 1 RCT, I2=0% conclusive unassessable degree of certainty	0.69 [0.56; 0.86], 1 RCT, I2=0% unassessable degree of certainty	-
	nivolumab alone vs. Standard of Care (SoC)	1	0.77 [0.62; 0.96], 1 RCT, I2=0% conclusive unassessable degree of certainty	1.08 [0.87; 1.34], 1 RCT, I2=0% inconclusive result	-
	pembrolizumab alone vs. Standard of Care (SoC)	1	0.89 [0.75; 1.05], 1 RCT, I2=0% inconclusive result	-	-